Diferencia entre revisiones de «Atorvastatin»
| (No se muestran 4 ediciones intermedias de 2 usuarios) | |||
| Línea 9: | Línea 9: | ||
*Moderate Intensity: 10-20 mg PO daily | *Moderate Intensity: 10-20 mg PO daily | ||
*High Intensity: 40-80 mg PO daily | *High Intensity: 40-80 mg PO daily | ||
===Acute | |||
===[[Acute coronary syndrome]]=== | |||
*80 mg PO (Single dose prior to PCI) | *80 mg PO (Single dose prior to PCI) | ||
| Línea 16: | Línea 17: | ||
==Special Populations== | ==Special Populations== | ||
*[[Pregnancy Rating]]: X | |||
*Pregnancy Rating: X | |||
*Lactation risk: Generally not recommended while breastfeeding | *Lactation risk: Generally not recommended while breastfeeding | ||
*Renal Dosing | *Renal Dosing | ||
| Línea 29: | Línea 29: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Hepatotoxicity | *[[Hepatotoxicity]] | ||
*Rhabdomyolysis | *[[Rhabdomyolysis]] | ||
===Common=== | ===Common=== | ||
*Arthralgias | *[[Arthralgias]] | ||
*Dyspepsia | *[[Dyspepsia]] | ||
*Nausea | *[[Nausea]] | ||
*UTI | *[[UTI]] | ||
*Insomnia | *[[Insomnia]] | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: Approximately 14 hours<ref>McIver LA, Siddique MS. Atorvastatin. [Updated 2022 Nov 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430779/</ref> | ||
*Metabolism: | *Metabolism: Metabolized by cytochrome CYP3A4 | ||
*Excretion: | *Excretion: Metabolites are eliminated via bile. | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Inhibits rate-limiting step in cholesterol biosynthesis by inhibiting HMG-COA reductase. | |||
*Additionally known to have "pleiotropic effects", which include plaque stabilization, improved endothelial function, decreased oxidative stress and inflammation, and thrombogenic response inhibition.<ref>Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118. doi: 10.1146/annurev.pharmtox.45.120403.095748. PMID: 15822172; PMCID: PMC2694580.</ref> | |||
==Comments== | ==Comments== | ||
Revisión actual - 20:26 13 sep 2023
Administration
- Type: Statins (HMG-CoA Reductase Inhibitor)
- Dosage Forms:
- Routes of Administration: PO
- Common Trade Names: Lipitor
Adult Dosing
Hyperlipidemia
- Moderate Intensity: 10-20 mg PO daily
- High Intensity: 40-80 mg PO daily
Acute coronary syndrome
- 80 mg PO (Single dose prior to PCI)
Pediatric Dosing
Special Populations
- Pregnancy Rating: X
- Lactation risk: Generally not recommended while breastfeeding
- Renal Dosing
- No adjustment
- Hepatic Dosing
- Contraindicated in patients with active liver disease
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life: Approximately 14 hours[1]
- Metabolism: Metabolized by cytochrome CYP3A4
- Excretion: Metabolites are eliminated via bile.
Mechanism of Action
- Inhibits rate-limiting step in cholesterol biosynthesis by inhibiting HMG-COA reductase.
- Additionally known to have "pleiotropic effects", which include plaque stabilization, improved endothelial function, decreased oxidative stress and inflammation, and thrombogenic response inhibition.[2]
Comments
See Also
References
- ↑ McIver LA, Siddique MS. Atorvastatin. [Updated 2022 Nov 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430779/
- ↑ Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118. doi: 10.1146/annurev.pharmtox.45.120403.095748. PMID: 15822172; PMCID: PMC2694580.